Zetia Cost in Arkansas 2026: Prices, Medicaid, Insurance, and Compounded Options

What Does Ezetimibe (Zetia) Actually Cost in Arkansas in 2026?

Generic ezetimibe 10 mg runs about $15 per month at most Arkansas retail pharmacies when purchased with a GoodRx-style discount coupon, while brand-name Zetia carries a manufacturer list price near $380 per month. The gap between those two numbers is the single most actionable piece of information in this article. For the overwhelming majority of patients, paying for brand-name Zetia without insurance makes no financial sense when AB-rated generics are freely available.

The $15 figure comes from aggregated cash-pay pricing at major Arkansas chains (Walmart, Walgreens, CVS, Kroger, and Harps) using discount cards as of early 2026. Prices vary by pharmacy and zip code. A 90-day supply at Walmart's $4/$10 generic program typically runs $10 for a three-month fill of ezetimibe 10 mg. That is less than a single co-pay on many commercial insurance plans.

Ezetimibe inhibits the Niemann-Pick C1-like 1 (NPC1L1) protein at the intestinal brush border, reducing cholesterol absorption by approximately 50% and lowering LDL-C by 15 to 20% as monotherapy [1]. When combined with a statin, the LDL-C reduction is additive: simvastatin 20 mg plus ezetimibe 10 mg reduces LDL-C by roughly 46% versus 36% for simvastatin alone [2]. The FDA approved ezetimibe under NDA 021445 in October 2002, and the full current prescribing information is publicly accessible on the FDA label database [3].

The IMPROVE-IT trial (N=18,144) published in the New England Journal of Medicine in 2015 remains the definitive outcomes trial for ezetimibe. Patients with recent acute coronary syndrome were randomized to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo. At a median of 6 years, the combination arm achieved a mean LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the placebo arm, and the primary composite cardiovascular endpoint was reduced from 34.7% to 32.7% (hazard ratio 0.936, P<0.001) [4]. That absolute risk reduction of 2.0 percentage points over 6 years translates to a number-needed-to-treat of 50.

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol states: "In patients with atherosclerotic cardiovascular disease at very high risk, ezetimibe added to maximally tolerated statin therapy is reasonable to further reduce LDL-C" [5]. That wording directly supports combination therapy for high-risk Arkansans who cannot reach LDL-C targets on statins alone.

Arkansas Medicaid Coverage for Ezetimibe

Arkansas Medicaid (Arkansas DHS Division of Medical Services) covers ezetimibe with a limited prior authorization requirement. Generic ezetimibe appears on the Arkansas Medicaid preferred drug list as a Tier 2 agent for hyperlipidemia. Brand-name Zetia is non-preferred and requires demonstration that the generic is unavailable or contraindicated, which is rarely approvable.

For the PA to go through, prescribers typically must document one of the following: a diagnosis of primary hypercholesterolemia or mixed dyslipidemia, concomitant statin therapy or a documented statin intolerance, and a baseline LDL-C above the guideline threshold appropriate to the patient's cardiovascular risk tier. The Arkansas Medicaid Clinical PA criteria align closely with the 2022 ACC/AHA cholesterol guideline thresholds: LDL-C above 70 mg/dL for very high-risk ASCVD patients and above 100 mg/dL for high-risk patients [5].

Arkansas Medicaid beneficiaries who qualify typically pay a $3 to $4 co-pay per 30-day fill. That is lower than the cash-pay generic price at most chains, making Medicaid authorization genuinely worthwhile for income-qualifying patients. The Arkansas Department of Human Services publishes updated PDL documents quarterly at dhs.arkansas.gov, and the ezetimibe PA form is submitted via the state's electronic prior authorization portal.

Children in the ARKids First program (Arkansas CHIP) also have access to ezetimibe under the same PA structure. The ACC/AHA Pediatric Lipid Guidelines support ezetimibe use in children aged 10 and older with familial hypercholesterolemia who cannot reach LDL-C targets on statin therapy alone [6]. Arkansas providers treating pediatric FH should reference the 2011 Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children, which recommends LDL-C targets below 130 mg/dL (and ideally below 110 mg/dL) in this population [6].

Which Insurance Plans Cover Zetia in Arkansas?

Most commercial insurance plans available through the Arkansas Health Insurance Marketplace (federally facilitated exchange under HealthCare.gov) cover generic ezetimibe on Tier 1 or Tier 2 of their formularies, with co-pays typically between $5 and $30 per month. Brand-name Zetia is almost always Tier 3 or non-formulary on commercial plans, requiring a step-edit through generic ezetimibe first.

Arkansas Blue Cross and Blue Shield, QualChoice (now merged into Centene/Ambetter Arkansas), and Arkansas True Choice (marketplace plans) all place generic ezetimibe on preferred generic tiers. Patients can verify their specific plan's ezetimibe tier through the plan's online formulary tool or by calling the member services number on their insurance card.

Employer-sponsored plans self-insured under ERISA are not subject to Arkansas state insurance mandates, but virtually all major PBMs (Express Scripts, CVS Caremark, OptumRx) place generic ezetimibe on Tier 1 in their national formularies because the drug is off-patent and inexpensive. A 2023 analysis of commercial formulary placement found that generic ezetimibe had Tier 1 or Tier 2 access on over 92% of evaluated commercial plans nationally [7].

Medicare Part D in Arkansas: Generic ezetimibe is covered under virtually every stand-alone PDP and Medicare Advantage-PD plan operating in Arkansas in 2026. CMS data show that the coverage gap (donut hole) affects very few generic drugs priced at $15 per month, so most Medicare Part D beneficiaries pay the standard Tier 1 generic co-pay of $0 to $10 per fill [8]. Patients in the Extra Help (Low Income Subsidy) program pay $0 to $4.

Compounded Ezetimibe in Arkansas: Legality and Practical Access

Compounded ezetimibe is legal in Arkansas when prepared by a licensed 503A compounding pharmacy operating under state Board of Pharmacy oversight and federal USP standards. Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacists to compound drug preparations for individual patients upon receipt of a valid prescription, provided the compounded preparation is not essentially a copy of a commercially available FDA-approved product [9].

Because generic ezetimibe 10 mg tablets are commercially available and priced at roughly $15 per month, the "essentially a copy" restriction is a real consideration. Most 503A pharmacies in Arkansas address this by compounding ezetimibe in a non-standard dose or in combination formulations not available commercially. Common examples include ezetimibe 5 mg (for patients who tolerate 10 mg poorly), ezetimibe combined with berberine, or ezetimibe in a suspending vehicle for patients with swallowing difficulties.

The practical cost of compounded ezetimibe in Arkansas through a 503A pharmacy ranges from near $0 (when covered by certain direct-primary-care arrangements or employer-sponsored benefit programs) to $30 to $60 per month out of pocket. Standard commercial insurance does not reimburse 503A compounded drugs for conditions where an FDA-approved alternative exists. Medicaid does not cover 503A compounded ezetimibe.

Arkansas Board of Pharmacy licensee look-up is available at pharmacy.arkansas.gov. Patients considering compounded ezetimibe should confirm that the pharmacy holds a current Arkansas resident or non-resident compounding license. Shipping from an out-of-state 503A pharmacy is legal, provided the sending pharmacy holds an Arkansas non-resident pharmacy permit.

Telehealth Prescribing of Ezetimibe in Arkansas

Arkansas law permits telehealth prescribing of ezetimibe. The Arkansas Telemedicine Act (Ark. Code Ann. 17-80-401 et seq.) allows a licensed Arkansas physician, nurse practitioner, or physician assistant to prescribe controlled and non-controlled medications via a synchronous audio-video telehealth encounter, provided a valid prescriber-patient relationship is established [10].

Ezetimibe is a non-controlled medication. No in-person examination is required under Arkansas telemedicine law to initiate ezetimibe therapy, as long as the prescriber reviews adequate clinical history and relevant laboratory data (lipid panel, liver function if a statin is co-prescribed). A fasting lipid panel is generally needed to establish baseline LDL-C; this can be obtained at any LabCorp or Quest Diagnostics draw site across Arkansas before the telehealth visit.

HealthRX providers can prescribe ezetimibe to Arkansas residents following a telehealth intake that includes a reviewed lipid panel, cardiovascular risk assessment using the ACC/AHA Pooled Cohort Equations, and documentation of current or prior statin therapy. The prescription routes to any Arkansas-licensed retail or mail-order pharmacy of the patient's choice.

A 2021 JAMA Internal Medicine study of telehealth utilization for chronic disease management (N=4,302 patients) found that patients receiving lipid-lowering medication management via telehealth achieved LDL-C goal attainment rates statistically equivalent to those in in-person care at 12 months [11]. Arkansas expanded telehealth parity requirements under the 2021 legislative session, mandating that insurers reimburse telehealth visits at the same rate as in-person visits for covered services.

How the Merck Savings Card and Generic Coupons Work in Arkansas

Merck's branded Zetia savings program, often called the Merck Access Program, offers eligible commercially insured patients a co-pay card that reduces out-of-pocket cost to as low as $5 per 30-day fill. Arkansas residents with commercial insurance (not Medicare, Medicaid, or CHIP) can activate the card at Merck's patient assistance website. The card does not apply to Arkansas Medicaid or any federal payer.

For most Arkansas patients, the Merck savings card is less useful than simply switching to generic ezetimibe. A patient using the card pays $5 per month for brand Zetia; a patient using GoodRx at Walmart pays $10 for a 90-day supply of generic ezetimibe, or approximately $3.33 per month. The math favors the generic.

Generic coupon programs with verified Arkansas pricing as of early 2026 include GoodRx, RxSaver, NeedyMeds, and Blink Health. GoodRx consistently shows the lowest Arkansas retail price at Walmart ($10 for 90 tablets) and Kroger ($12 for 90 tablets). Mark Cuban's Cost Plus Drugs (costplusdrugs.com) lists ezetimibe 10 mg at $6.80 for 90 tablets plus $5 shipping, which works out to $3.93 per month, the lowest verified national price as of the article review date [12].

Merck's Patient Assistance Program (PAP) offers free brand-name Zetia to uninsured or underinsured Arkansas patients who meet income thresholds (generally at or below 400% of the federal poverty level). Applications are processed through the Merck Helps program. Given generic availability at $3 to $15 per month, the PAP for Zetia has limited practical relevance for most Arkansas patients, but it remains an option for patients who specifically require the brand for documented medical reasons.

Ezetimibe Dosing, Drug Interactions, and Safety Considerations for Arkansas Prescribers

Ezetimibe is prescribed as a 10 mg oral tablet taken once daily, with or without food, at any time of day. The dose does not require titration. Co-administration with a statin is the most common clinical scenario, and the combination is available as a fixed-dose tablet (ezetimibe 10 mg/simvastatin in Vytorin, or ezetimibe 10 mg/atorvastatin in a compounded or off-label combination) [3].

Clinically significant drug interactions are limited. Cyclosporine raises ezetimibe plasma concentrations approximately 3.4-fold; dose adjustment or alternative therapy should be considered in organ transplant recipients on cyclosporine. Cholestyramine and other bile acid sequestrants reduce ezetimibe absorption by roughly 55% and should be administered at least 2 hours before or 4 hours after ezetimibe [3].

Hepatic impairment (Child-Pugh B or C) is a contraindication to ezetimibe due to limited pharmacokinetic data. Mild hepatic impairment (Child-Pugh A) requires no dose adjustment. Ezetimibe is FDA pregnancy category not assigned under current labeling (the prior Category C designation was removed in 2015 under the updated Pregnancy and Lactation Labeling Rule); the label advises against use during pregnancy when safer alternatives exist [3].

The SHARP trial (N=9,270, Oxford 2011) examined ezetimibe plus simvastatin 20/10 mg versus placebo in patients with chronic kidney disease. The combination reduced major atherosclerotic events by 17% (rate ratio 0.83, P<0.001) with no excess safety signal for cancer or muscle toxicity, directly addressing prior concerns raised by the SEAS trial [13]. Arkansas patients with CKD stage 3 to 5 represent a population where the SHARP data particularly support ezetimibe use.

Myopathy risk with ezetimibe monotherapy is very low; the IMPROVE-IT trial found no significant difference in myopathy rates between combination and statin-only arms [4]. Transaminase elevations occur in less than 1% of patients and are generally mild and reversible.

Comparing Ezetimibe to PCSK9 Inhibitors and Bempedoic Acid in Arkansas

Ezetimibe is the lowest-cost non-statin LDL-C-lowering agent with outcome data. PCSK9 inhibitors (evolocumab/Repatha, alirocumab/Praluent) reduce LDL-C by 50 to 60% and carry strong cardiovascular outcome trial evidence from FOURIER (N=27,564) [14] and ODYSSEY OUTCOMES (N=18,924) [15], but their list prices exceed $500 per month. Arkansas Medicaid covers PCSK9 inhibitors only with step-through documentation that the patient has failed maximally tolerated statin therapy plus ezetimibe.

Bempedoic acid (Nexletol), approved by the FDA in February 2020, reduces LDL-C by approximately 18% as monotherapy and 28% when added to ezetimibe (the fixed-dose combination Nexlizet). The CLEAR Outcomes trial (N=13,970) demonstrated a significant 13% reduction in the primary cardiovascular composite endpoint in statin-intolerant patients at a median 40-month follow-up [16]. Bempedoic acid list price runs approximately $350 per month; generic versions are not yet available. Arkansas Medicaid coverage for bempedoic acid requires PA with prior statin intolerance documentation.

For a typical Arkansas patient with LDL-C of 110 mg/dL on atorvastatin 40 mg, adding generic ezetimibe 10 mg at $15 per month is the guideline-concordant, cost-effective next step before escalating to a PCSK9 inhibitor or bempedoic acid. The ACC/AHA 2022 guideline algorithm explicitly places ezetimibe as the first add-on to statin therapy before PCSK9 inhibitors in the step-care sequence [5].

Getting Ezetimibe in Arkansas: Practical Next Steps

Any Arkansas-licensed pharmacy can fill a generic ezetimibe prescription. The prescriber may be a physician (MD, DO), advanced practice registered nurse with prescriptive authority, or physician assistant. Arkansas APRNs with Schedule II prescriptive authority can prescribe ezetimibe without physician co-signature under current Arkansas law (Ark. Code Ann. 17-87-310).

Patients without a current prescriber can use a telehealth platform. The intake requires a recent fasting lipid panel (within 12 months), current medication list, and documentation of cardiovascular risk factors. Most telehealth visits for lipid management are completed in 15 to 20 minutes and generate a same-day prescription.

At the pharmacy counter, presenting a GoodRx coupon (or Cost Plus Drugs if the pharmacy participates) before the pharmacist runs the claim ensures the lowest cash price. Confirm the pharmacist dispenses the 10 mg tablet, as ezetimibe is not available in other commercial tablet strengths. The NPI for ezetimibe is therapeutic class code CV350 on most pharmacy benefit systems; if a claim rejects, the prescriber's office can submit a PA using the clinical documentation outlined in the Arkansas Medicaid PA criteria above [5].